Department of Epidemiology and Environmental Health, University at Buffalo School of Public Health and Health Professions, Buffalo, New York, USA.
Department of Pharmacy Practice, University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York, USA.
Pharmacoepidemiol Drug Saf. 2021 Aug;30(8):1049-1056. doi: 10.1002/pds.5201. Epub 2021 Feb 16.
Previous studies have demonstrated increasing mortality due to falls among older adults. The objective of this study was to determine whether there was an increase in fall risk increasing drug prescribing and if this is concurrent with an increase in fall-related mortality in persons 65 years and older in the United States.
The study is a serial cross-sectional analysis utilizing data from both the National Vital Statistics System (NVSS) and the medical expenditure panel survey (MEPS) for years 1999-2017. Adults aged 65 years and older were evaluated for death due to falls from the NVSS and for prescription fills of fall risk increasing drugs per the Stopping Elderly Accidents, Deaths, and Injuries-Rx (STEADI-Rx) fall checklist from the MEPS.
The analysis included 374 972 fall-related mortalities and 7 858 177 122 fills of fall risk increasing drugs. 563 037 964 persons age 65 and older received at least one fall risk increasing drug. Age-adjusted mortality due to falls increased from 29.40 per 100 000 in 1999 to 63.27 per 100 000 in 2017. The percent of persons who received at least one prescription for a fall risk increasing drug increased from 57% in 1999 to 94% in 2017 (p for trend <.0001).
Both use of fall risk increasing drugs and mortality due to falls are on the rise. Fall risk increasing drugs may partially explain the increase in mortality due to falls; this cannot be firmly concluded from the current study. Future research examining the potential relationship between fall risk increasing drugs and fall-related mortality utilizing nationally representative person-level data are needed.
先前的研究表明,老年人因跌倒而导致的死亡率不断上升。本研究旨在确定是否存在因跌倒风险增加而导致的药物处方增加的情况,以及这种情况是否与美国 65 岁及以上人群中与跌倒相关的死亡率增加有关。
本研究采用了 1999 年至 2017 年期间来自国家生命统计系统(NVSS)和医疗支出面板调查(MEPS)的数据进行了一项连续的横断面分析。使用 NVSS 评估了成年人因跌倒导致的死亡情况,使用 MEPS 的 STOPPING ELDERLY ACCIDENTS, DEATHS, AND INJURIES-Rx(STEADI-Rx)跌倒清单评估了跌倒风险增加药物的处方数量。
该分析共纳入了 374972 例与跌倒相关的死亡病例和 7858177122 例跌倒风险增加药物的处方数量。563037964 名 65 岁及以上的老年人至少使用了一种跌倒风险增加药物。因跌倒导致的死亡率从 1999 年的每 10 万人 29.40 例上升至 2017 年的每 10 万人 63.27 例。至少使用一种跌倒风险增加药物处方的人数比例从 1999 年的 57%上升至 2017 年的 94%(趋势 P <.0001)。
使用跌倒风险增加药物和因跌倒导致的死亡率都在上升。跌倒风险增加药物可能部分解释了因跌倒导致的死亡率增加;但从目前的研究中无法得出明确的结论。需要利用全国代表性的个人层面数据,进一步研究评估跌倒风险增加药物与与跌倒相关的死亡率之间的潜在关系。